^
No biomarker
Prostate Cancer
olaparib
Sensitive: B - Late Trials
Merck (MSD) Press Release - 3 weeks
No biomarker
Prostate Cancer
apalutamide
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
histrelin acetate
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
cabazitaxel
Sensitive: A1 - Approval
BRCA2 mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
BRCA1 mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
enzalutamide
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
relugolix
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
docetaxel + prednisone
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
abiraterone acetate
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
degarelix
Sensitive: A1 - Approval
ATM mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
darolutamide
Sensitive: A1 - Approval
BRCA1 mutation
Prostate Cancer
rucaparib
Sensitive: A1 - Approval
BRCA2 mutation
Prostate Cancer
rucaparib
Sensitive: A1 - Approval
HRD
Prostate Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
zoledronic acid
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
leuprolide mesylate injectable suspension
Sensitive: A1 - Approval
MSI-H/dMMR
Prostate Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
mitoxantrone
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
etoposide IV
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
atezolizumab
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
docetaxel
Sensitive: A2 - Guideline
CDK12 mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
PALB2 mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
CHEK2 mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
CHEK1 mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
AR splice variant 7
Prostate Cancer
abiraterone acetate
Resistant: A2 - Guideline
AR splice variant 7
Prostate Cancer
enzalutamide
Resistant: A2 - Guideline
RAD51B mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
RAD51C mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
RAD51D mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
RAD54L mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
FANCL mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
BRIP1 mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
BARD1 mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
PPP2R2A mutation
Prostate Cancer
olaparib
Resistant: A2 - Guideline
No biomarker
Prostate Cancer
sipuleucel-T
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
histrelin acetate + nilutamide
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
bicalutamide + goserelin acetate
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
goserelin acetate + flutamide
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
goserelin acetate + nilutamide
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
triptorelin
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
leuprolide acetate
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
goserelin acetate
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
abiraterone acetate + degarelix
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
abiraterone acetate + triptorelin
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
abiraterone acetate + leuprolide acetate
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
abiraterone acetate + histrelin acetate
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
abiraterone acetate + goserelin acetate
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
bicalutamide + triptorelin
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
triptorelin + flutamide
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
triptorelin + nilutamide
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
leuprolide acetate + bicalutamide
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
leuprolide acetate + flutamide
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
leuprolide acetate + nilutamide
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
bicalutamide + histrelin acetate
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
histrelin acetate + flutamide
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
carboplatin + docetaxel
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
carboplatin + etoposide oral
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
cisplatin + etoposide oral
Sensitive: A2 - Guideline
TMB-H
Prostate Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
carboplatin + cabazitaxel
Sensitive: A2 - Guideline
AR amplification
Prostate Cancer
enzalutamide
Resistant: B - Late Trials
BRCA1 mutation
Prostate Cancer
niraparib
Sensitive: B - Late Trials
BRCA2 mutation
Prostate Cancer
niraparib
Sensitive: B - Late Trials
No biomarker
Prostate Cancer
CYP17A1 inhibitor
Sensitive: B - Late Trials
No biomarker
Prostate Cancer
RV001
Sensitive: B - Late Trials
PTEN mutation
Prostate Cancer
bicalutamide
Sensitive: B - Late Trials
PTEN loss
Prostate Cancer
GDC-0068 + AST-2970 + prednisolone
Sensitive: B - Late Trials
No biomarker
Prostate Cancer
EPI-7386
Sensitive: B - Late Trials
No biomarker
Prostate Cancer
ipilimumab
Sensitive: B - Late Trials
AR amplification
Prostate Cancer
AST-2970
Resistant: B - Late Trials
TP53 deletion
Prostate Cancer
abiraterone acetate
Resistant: B - Late Trials
TP53 deletion
Prostate Cancer
enzalutamide
Resistant: B - Late Trials
RB1 deletion
Prostate Cancer
abiraterone acetate
Resistant: B - Late Trials
RB1 deletion
Prostate Cancer
enzalutamide
Resistant: B - Late Trials
BRCA2 deletion
Prostate Cancer
enzalutamide
Sensitive: B - Late Trials
BRCA2 deletion
Prostate Cancer
abiraterone acetate
Sensitive: B - Late Trials
BRCA1 positive
Prostate Cancer
olaparib
Sensitive: B - Late Trials
BRCA2 positive
Prostate Cancer
olaparib
Sensitive: B - Late Trials
ATM positive
Prostate Cancer
olaparib
Sensitive: B - Late Trials
PTEN negative
Prostate Cancer
GDC-0068
Sensitive: B - Late Trials
FOLH1 positive
Prostate Cancer
177 Lu PSMA-617
Sensitive: B - Late Trials
No biomarker
Prostate Cancer
177 Lu PSMA-617
Sensitive: B - Late Trials
PTEN deletion
Prostate Cancer
GDC-0068
Sensitive: B - Late Trials
PD-L1 expression
Prostate Cancer
pembrolizumab
Sensitive: C1 - Off-label
PD-L1 expression
Prostate Cancer
durvalumab
Sensitive: C1 - Off-label
MSI-H/dMMR
Prostate Cancer
nivolumab
Sensitive: C1 - Off-label
BRCA2 mutation
Prostate Cancer
talazoparib
Sensitive: C1 - Off-label
PD-L1 expression
Prostate Cancer
nivolumab + ipilimumab
Sensitive: C1 - Off-label
BRCA1 mutation
Prostate Cancer
talazoparib
Sensitive: C1 - Off-label
ATM mutation
Prostate Cancer
talazoparib
Sensitive: C2 – Inclusion Criteria